# Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

> **NCT04640311** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 259 (actual)

## Conditions studied

- Anaemia

## Interventions

- **DRUG:** Daprodustat

## Key facts

- **NCT ID:** NCT04640311
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-18
- **Primary completion:** 2021-05-18
- **Final completion:** 2021-05-18
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640311, "Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04640311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*